Current Research Studies

Cancer – H-42691: A Trial of Atovaquone (MEPRON) Combined with Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents and Young Adults

Condition or Therapy:

Acute Myeloid Leukemia (AML)


Cancer and Blood Disorders
Study Number: H-42691


What is the goal of this study?

The goals of this study are:

  • To collect data on the patient and family experience of giving daily atovaquone to patients during their first month of AML treatment.
  • To collect information about whether atovaquone kills cancer cells from children with AML, using research laboratory studies.
  • To learn more about how atovaquone kills cancer cells from children with AML.
  • To help determine the best way to include atovaquone in pediatric AML treatments in the future.

Who can join the study?

This study may be a good fit for children and young adults who:

  • Are between 1 month and 21 years old
  • Are newly diagnosed with acute myelogenous leukemia

What will happen if my child takes part in this study?

You can read more about this study on

Who can I contact for more information?

To learn more, call 206-987-2106 or email the study coordinator.

Study Location(s):

Seattle Children's Main Hospital Campus

Principal Investigator:

Dr. Todd Cooper
Research Center: Center for Clinical and Translational Research